Cargando…
Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas
SIMPLE SUMMARY: Soft tissue sarcomas (STSs) are rare and highly heterogeneous tumors that are difficult to treat. Gemcitabine plus docetaxel is an effective treatment for advanced STS. However, the prognosis for patients remains poor, and thus there is an urgent medical need for novel and effective...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572019/ https://www.ncbi.nlm.nih.gov/pubmed/37835565 http://dx.doi.org/10.3390/cancers15194871 |
_version_ | 1785120138147659776 |
---|---|
author | Attia, Steven Villalobos, Victor Hindi, Nadia Wagner, Andrew J. Chmielowski, Bartosz Oakley, Gerard J. Peterson, Patrick M. Ceccarelli, Matteo Jones, Robin L. Dickson, Mark A. |
author_facet | Attia, Steven Villalobos, Victor Hindi, Nadia Wagner, Andrew J. Chmielowski, Bartosz Oakley, Gerard J. Peterson, Patrick M. Ceccarelli, Matteo Jones, Robin L. Dickson, Mark A. |
author_sort | Attia, Steven |
collection | PubMed |
description | SIMPLE SUMMARY: Soft tissue sarcomas (STSs) are rare and highly heterogeneous tumors that are difficult to treat. Gemcitabine plus docetaxel is an effective treatment for advanced STS. However, the prognosis for patients remains poor, and thus there is an urgent medical need for novel and effective therapies to improve long-term outcomes. The aim of the ANNOUNCE 2 trial was to explore the addition of olaratumab (O) to gemcitabine (G) and docetaxel (D) for advanced STS. Patients were randomized 1:1 from two cohorts (O-naïve and O-pretreated) to 21-day cycles of olaratumab, gemcitabine, and docetaxel. A total of 167 and 89 patients were enrolled in the O-naïve and O-pretreated cohorts, respectively. There was no statistically significant difference in the primary endpoint of overall survival between the two arms in the O-naïve population. No new safety signals were observed. ABSTRACT: Gemcitabine plus docetaxel is an effective treatment regimen for advanced soft tissue sarcomas (STSs). However, the prognosis for patients remains poor, and thus there is an urgent medical need for novel and effective therapies to improve long-term outcomes. The aim of the ANNOUNCE 2 trial was to explore the addition of olaratumab (O) to gemcitabine (G) and docetaxel (D) for advanced STS. Adults with unresectable locally advanced/metastatic STS, ≤2 prior lines of systemic therapy, and ECOG PS 0–1 were eligible. In Phase 2, patients were randomized 1:1 from two cohorts (O-naïve and O-pretreated) to 21-day cycles of olaratumab (20 mg/kg Cycle 1 and 15 mg/kg other cycles, Days 1 and 8), gemcitabine (900 mg/m(2), Days 1 and 8), and docetaxel (75 mg/m(2), Day 8). The primary objective was overall survival (OS) in the O-naïve population (α level = 0.20). Secondary endpoints included OS (O-pretreated), other efficacy parameters, patient-reported outcomes, safety, pharmacokinetics, and immunogenicity. A total of 167 and 89 patients were enrolled in the O-naïve and O-pretreated cohorts, respectively. Baseline patient characteristics were well balanced. No statistically significant difference in OS was observed between the investigational vs. control arm for either cohort (O-naïve cohort: HR = 0.95 (95% CI: 0.64−1.40), p = 0.78, median OS, 16.8 vs. 18.0 months; O-pretreated cohort: HR = 0.67 (95% CI: 0.39−1.16), p = 0.15, median OS 19.8 vs. 17.3 months). Safety was manageable across treatment arms. There was no statistically significant difference in the primary endpoint of OS between the two arms in the O-naïve population, and therefore based on hierarchical evaluation no other outcomes in this study can be considered statistically significant. No new safety signals were observed. |
format | Online Article Text |
id | pubmed-10572019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105720192023-10-14 Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas Attia, Steven Villalobos, Victor Hindi, Nadia Wagner, Andrew J. Chmielowski, Bartosz Oakley, Gerard J. Peterson, Patrick M. Ceccarelli, Matteo Jones, Robin L. Dickson, Mark A. Cancers (Basel) Article SIMPLE SUMMARY: Soft tissue sarcomas (STSs) are rare and highly heterogeneous tumors that are difficult to treat. Gemcitabine plus docetaxel is an effective treatment for advanced STS. However, the prognosis for patients remains poor, and thus there is an urgent medical need for novel and effective therapies to improve long-term outcomes. The aim of the ANNOUNCE 2 trial was to explore the addition of olaratumab (O) to gemcitabine (G) and docetaxel (D) for advanced STS. Patients were randomized 1:1 from two cohorts (O-naïve and O-pretreated) to 21-day cycles of olaratumab, gemcitabine, and docetaxel. A total of 167 and 89 patients were enrolled in the O-naïve and O-pretreated cohorts, respectively. There was no statistically significant difference in the primary endpoint of overall survival between the two arms in the O-naïve population. No new safety signals were observed. ABSTRACT: Gemcitabine plus docetaxel is an effective treatment regimen for advanced soft tissue sarcomas (STSs). However, the prognosis for patients remains poor, and thus there is an urgent medical need for novel and effective therapies to improve long-term outcomes. The aim of the ANNOUNCE 2 trial was to explore the addition of olaratumab (O) to gemcitabine (G) and docetaxel (D) for advanced STS. Adults with unresectable locally advanced/metastatic STS, ≤2 prior lines of systemic therapy, and ECOG PS 0–1 were eligible. In Phase 2, patients were randomized 1:1 from two cohorts (O-naïve and O-pretreated) to 21-day cycles of olaratumab (20 mg/kg Cycle 1 and 15 mg/kg other cycles, Days 1 and 8), gemcitabine (900 mg/m(2), Days 1 and 8), and docetaxel (75 mg/m(2), Day 8). The primary objective was overall survival (OS) in the O-naïve population (α level = 0.20). Secondary endpoints included OS (O-pretreated), other efficacy parameters, patient-reported outcomes, safety, pharmacokinetics, and immunogenicity. A total of 167 and 89 patients were enrolled in the O-naïve and O-pretreated cohorts, respectively. Baseline patient characteristics were well balanced. No statistically significant difference in OS was observed between the investigational vs. control arm for either cohort (O-naïve cohort: HR = 0.95 (95% CI: 0.64−1.40), p = 0.78, median OS, 16.8 vs. 18.0 months; O-pretreated cohort: HR = 0.67 (95% CI: 0.39−1.16), p = 0.15, median OS 19.8 vs. 17.3 months). Safety was manageable across treatment arms. There was no statistically significant difference in the primary endpoint of OS between the two arms in the O-naïve population, and therefore based on hierarchical evaluation no other outcomes in this study can be considered statistically significant. No new safety signals were observed. MDPI 2023-10-06 /pmc/articles/PMC10572019/ /pubmed/37835565 http://dx.doi.org/10.3390/cancers15194871 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Attia, Steven Villalobos, Victor Hindi, Nadia Wagner, Andrew J. Chmielowski, Bartosz Oakley, Gerard J. Peterson, Patrick M. Ceccarelli, Matteo Jones, Robin L. Dickson, Mark A. Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas |
title | Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas |
title_full | Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas |
title_fullStr | Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas |
title_full_unstemmed | Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas |
title_short | Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas |
title_sort | randomized phase 2 clinical trial of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcomas |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572019/ https://www.ncbi.nlm.nih.gov/pubmed/37835565 http://dx.doi.org/10.3390/cancers15194871 |
work_keys_str_mv | AT attiasteven randomizedphase2clinicaltrialofolaratumabincombinationwithgemcitabineanddocetaxelinadvancedsofttissuesarcomas AT villalobosvictor randomizedphase2clinicaltrialofolaratumabincombinationwithgemcitabineanddocetaxelinadvancedsofttissuesarcomas AT hindinadia randomizedphase2clinicaltrialofolaratumabincombinationwithgemcitabineanddocetaxelinadvancedsofttissuesarcomas AT wagnerandrewj randomizedphase2clinicaltrialofolaratumabincombinationwithgemcitabineanddocetaxelinadvancedsofttissuesarcomas AT chmielowskibartosz randomizedphase2clinicaltrialofolaratumabincombinationwithgemcitabineanddocetaxelinadvancedsofttissuesarcomas AT oakleygerardj randomizedphase2clinicaltrialofolaratumabincombinationwithgemcitabineanddocetaxelinadvancedsofttissuesarcomas AT petersonpatrickm randomizedphase2clinicaltrialofolaratumabincombinationwithgemcitabineanddocetaxelinadvancedsofttissuesarcomas AT ceccarellimatteo randomizedphase2clinicaltrialofolaratumabincombinationwithgemcitabineanddocetaxelinadvancedsofttissuesarcomas AT jonesrobinl randomizedphase2clinicaltrialofolaratumabincombinationwithgemcitabineanddocetaxelinadvancedsofttissuesarcomas AT dicksonmarka randomizedphase2clinicaltrialofolaratumabincombinationwithgemcitabineanddocetaxelinadvancedsofttissuesarcomas |